Posted by Michael Wonder on 18 Dec 2024
FDA grants fast track designation to Lipocine for LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis
17 December 2024 - Lipocine today announced that the US FDA has granted fast track designation to LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis.
LPCN 1148, an oral pro-drug of bio-identical testosterone, was recently studied in a proof of concept Phase 2 study in patients with decompensated cirrhosis.
